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Background: Mutation(s) of the JAK2 gene (V617F) has been described in a significant proportion of Philadelphia
negative Myeloproliferative Neoplasms (MPN) patients and its detection is now a cornerstone in the diagnostic
algorithm.
Methods: We developed a novel assay based on peptide nucleic acid (PNA) technology coupled to immuno-
fluorescence microscopy (PNA-FISH) for the specific detection at a single cell level of JAK2-mutation thus improving
both the diagnostic resolution and the study of clonal prevalence.
Results: Using this assay we found a percentage of mutated CD34+ cells ranging from 40% to 100% in
Polycythemia Vera patients, from 15% to 80% in Essential Thrombocythemia and from 25% to 100% in Primary
Myelofibrosis. This method allows to distinguish, with a high degree of specificity, at single cell level, between
CD34+ progenitor stem cells harbouring the mutated or the wild type form of JAK2 in NPM patients.
Conclusions: This method allows to identify multiple gene abnormalities which will be of paramount relevance to
understand the pathophysiology and the evolution of any type of cancer.
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Ph-negative MPNs include Essential Thrombocytemia,
Polycythemia Vera and Primary Myelofibrosis. They
share a common molecular signature represented by the
mutation of JAK2 [1-4]. The detection JAK2V617 is in-
cluded in the diagnostic criteria and specific JAK2 inhib-
itors have been recently approved for the treatment of
these patients [1]. MPNs are currently considered stem
cell-related disorders of monoclonal origin although the
presence of different co-existing subclones cannot be
ruled out. Interestingly, in patients bearing JAK2V617F
within the CD34+ compartment a mosaicism of cells
harbouring the JAK2V617F can be detected alongside with* Correspondence: daniela.cilloni@unito.it
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reproduction in any medium, provided the orthe wild type counterparts, as elegantly reported by Scott
and colleagues [5]. Nevertheless current approaches do
not discriminate these two populations or directly quantify
them in a easy and affordable format. In particular, the
available methodology forecasts the use of colony forma-
tion assays followed by capillary electrophoresis sequen-
cing [5,6]. Overall, this method owns some pitfalls which
are primarily due to: i) time consuming sample processing
and ii) relatively low abundance of DNA isolated from col-
onies, iii) culture conditions (i.e. Epo +/−) may alter the
proportion of colonies bearing the mutation. On the other
hand, the method most frequently used for measuring the
distribution of cell populations is indirect and based on
JAK2 sequencing. The JAK2V617F allele-burden is usually
estimated by allele specific polymerase chain reaction
(PCR). Although it is a sensitive assay, this is performed
on the whole ‘white’ myeloid differentiated cell population
(e.g. granulocytes) and for this reason it may be biased by
‘dilution effects’ on sample. For all this reasons, the chanceLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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still represents a challenge, both in the diagnostic and re-
search field. The PNA is a synthetic nucleic acid analogue
in which the negatively charged sugar phosphate back-
bone is replaced by a neutral pseudo-peptide backbone
[7]. Due to its (i) high degree of sequence selectivity, (ii)
discrimination ability in binding to complementary DNA
or RNA, and (iii) increased stability (relative to non-
synthetic nucleic acids) and (iiii) low cost, PNA probes do
have tremendous potential for therapeutic application as
well as diagnostic and research use, especially when a
highly specific matching is needed. The physical proper-
ties of PNA endow them with specific advantages over
standard oligonucleotides probes: they are less polar than
(natural) nucleic acids and -as a consequence- PNA/DNA
heteroduplexes are thermodynamically favoured when
compared to the DNA/DNA double helix [8]. When very
short PNA are used, this greater specificity allows the
PNA/DNA heteroduplex to become thermodynamicallyFigure 1 Detection of JAK2 mutation by PNA. Detection of JAK2V617F m
affected by Essential Thrombocytemia (ET), (A, B), Primary myelofibrosis (PM
represented by a non JAK2 mutated MPN patient. No specific PNA green sunstable even when a single base-pair mismatch occurs
[9]. Taking advantage of these unique PNA features we
set-up a fluorescently-labelled PNA probe, coupled to
FISH technology, to identify the presence of JAK2V617F
at the single-cell level. This method allows to distin-
guish between CD34+ progenitor stem cells harbouring
the mutated or wild type form of JAK2 (Figure 1).
In this article we report a method characterized by a
high degree of specificity and sensitivity which allows to
identify at a single cell level the presence of JAK2V617F
mutation.
Results and discussion
CD34+ cells from JAK2V617F positive patients (affected
by ET, PV and PMF) displayed an heterogeneous stain-
ing pattern when probed with the JAK2V617F/PNA. In-
deed, in a single patient some CD34+ cells are clearly
positive for JAK2V617F/PNA-fluorescent staining, while
others are negative (Figure 2). The analysis revealed thatutation by PNA (green signal) in CD34+ cells enriched from patients
F) (C, D) Polycytemia Vera (PV) (E, F). Negative control (G, H) is
ignal can be detected in the absence of JAK2V617F mutation.
Figure 2 PNA distinguishes between CD34+ cells with and without JAK2 mutation in PV patient. Detection of JAK2V617F mutation by PNA
(green signal) in some CD34+ cells enriched from patients affected by Polycytemia Vera (B, D). Red Arrows in panels (A, C) indicate CD34+ cells
without the JAK2 mutation. The percentage of PNA positive and negative cells are variable among patients and in different diseases.
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fairly similar to that reported by Scott et al. [5] with a
rather wide variability occurring among patients. We
found a percentage of mutated CD34+ cells ranging
from 40% to 100% in PV patients, from 15% to 80% in
ET and from 25% to 100% in PMF. These findings are in
agreement with previous data reporting that a variable
proportion of progenitors from patients affected by
JAK2V617F positive PV are capable of generating JAK2V617F
negative colonies [5]. In addition these data indicate that
fluorescinated JAK2V617F/PNA probe displays a very high
specificity towards a single base-pair mismatch.
Interestingly, when evaluating the presence of
JAK2V617Fpositive cells collected from JAK2 wild type
subjects defined by sequencing and by Q-PCR we identi-
fied a small percentage of cells positive for the JAK2V617F/
PNA staining not exceeding 3% of the CD34+ cell popula-
tion indicating a high level of sensitivity of the procedure.
Interestingly, this apply only to patients with PV but not
with PMF and ET. Importantly, the lack of positivity
detected in CD34+ cells from 20 healthy subjectsdemonstrates a high specificity of this method. We con-
clude that the JAK2V617F/PNA-FISH method displays high
specificity and reliability in discriminating cell subpopula-
tions harbouring the JAK2V617F mutation. In addition, it
allows to analyze the CD34+ population at the single cell
level, avoiding the time consuming analysis of hema-
topoietic colonies. The fact that our results are in keeping
with the data reported by Scott et al [5] corroborate the
robustness of the technique although we think that the
proposed approach is much easier and free from variabil-
ity related to colony growth conditions [5,6]. This ap-
proach allows to monitor longitudinally the evolution of a
defined cell population over time in MPNs.
Conclusions
This study presents a novel PNA-FISH protocol which al-
lows to characterize the CD34+ compartment in patients
with MPNs. These data could improve the knowledge on
the pathophysiology of MPNs and will improve both the
diagnostic and discovery tools. In addition, our approach
allows the identification of specific genetic (or gene)
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since in the great majority of neoplasm a technique equiva-
lent to the in vitro growth of progenitor cells is unavailable.
Methods
Patients
Local ethic committee San Luigi Gonzaga, Piedmont
Region, approved the study (approval number 203). After
informed consent BM aspirates were obtained from 24 PV
patients (5 of them were selected for the absence of
JAK2V617F ), 13 PMF (3 of them were JAK2 wild type) and
6 ET patients (2 of them were wild type). In addition 20
BM samples were collected from healthy donors and used
as control.
CD34+ enrichment
CD34+ cells were enriched by magnetic cell sorting
(MACS) (Miltenyi Biotec, Bergisch Gladbach, Germany)
according to the manufacturer’s protocol.
Capillary Sanger sequence method for the detection of
JAK2V617F
Detection of JAK2V617F was performed by capillary
Sanger Sequence method. JAK2V617F mutation was amp-
lified using primers described by Baxter and colleagues
[4] and analyzed by sequencing with BigDye terminator
v3.1 (Applied Biosystem, Foster City, California CA) and
capillary electrophoresis on ABI PRISM 3130XL (Ap-
plied Biosystem, Foster City, California CA). The sensi-
tivity of this method was previously estimated by serial
dilutions experiments to be 10%.
Quantitative PCR
Q-PCR was performed by making use of JAK2 Muta-
Quant kit (Ipsogen, Marseille, France) based on Taqman
technology according to the manufactures’ procedure.
The signal is measured on a standard curve. The sensi-
tivity of this method was estimate to be 0.1%.
Design and sequence of JAK2V617F PNA probe
PNA probe, designed on the human JAK2 cDNA (acc. #
NM_004972), encompasses a very short sequence (12 nu-
cleotides) just over the codon 617 (bp 1849 when referring
to the coding sequence) responsible for the V- > F muta-
tion. The single nucleotide mismatch falls just in the mid-
dle of the sequence. The probe has been further tagged by
fluorescinated dye at its amino-terminus. The sequence is
as follow: Alexa488-OO-GTATGTTTCTGT-Lys.
Protocol for JAK2V617F detection using a specific PNA
probe
1. Fiveml cell culture medium were prepared
usingrpmI medium enriched with 20% Fetal BovineSerum (FBS). Oneml of fresh marrow blood was put
in culture. CD34+ cells were enriched from bone
marrow aspirates by magnetic cell sorting (MACS;
Miltenyi Biotec, Bergisch Gladbach, Germany)
following the manufacture’s instruction.
2. CD34+ were incubated over night (ON) at 37 C in
5% CO2 atmosphere.
3. Cells were harvest by centrifugation (1500 rpm for
7 minutes).
4. Supernatant was carefully removed.
5. Fiveml (Phosphate Buffer Saline) PBS was added and
cells re-suspended.
6. Cells were harvested by centrifugation as in step 3.
7. Pellet was re-suspend in 10 ml of 75 mM KCl, and
incubated at 37°C for 20 minutes.
Note: Mix carefully by vortexing.
8. Cells were harvest by centrifugation as previously
described in step 3.
9. Supernatant was removed.
10. Threeml of a freshly made Methanol ice cold:acetic
acid (3:1) solution were added.
Note: Prepare just before use. It is very important
adding the methanol:acetic acid very carefully and
slowly.
11. Cells were harvest by centrifugation.
12. Supernatant was removed
13. Steps 10, 11, 12 were repeated four times.
14. Cells re-suspended in acetic acid solution and
Cytospun on slides (500 rpm for 10 minutes;
at least 10 [5] cells per slide).
15. Slides were immersed in 2X SSC (Sodium Citrate
Solution, Invitrogen) solution at 37°C for 30 minutes.
16. Slides were dehydrated in cold ethanol series (for
2 minutes each in 70%, 80%, 90%).
Note: Avoid to drying slides during serial passages.
17. Slides were dried on air.
18. Threeml PNA probe were added to each slides
(final concentration 200 nM).
19. Slides were covered with a coverslip and seal with
glue (Rubber Cement, Fixogum, LK-071°
KREATECH diagnostics).
Note: Be careful: after adding PNA maintain the slides
in dark to avoid fluorescence bleaching.
20. DNA was denatured by incubating the slide for
2 minutes at 82°C and then incubate ON at 37°C.
21. Coverslips were removed.
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at 65°C.
23. Slides were washed the in PBS 1X at room
temperature for 30 seconds.
24. Step 23 was repeated (× 3).
25. Coverslip was used to allow the solution to spread
evenly under the coverslip. Avoid air bubbles.
Note: Slides were placed in the dark at 4°C for at least
couple of hours.
26. Stained slide were analyzed by using an
fluorescence microscope with appropriate filters.
27. Slides were stored the in the dark at 4°C up to few
weeks.
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